|
|
Article: IL-13 cytotoxin used for malignant glioma therapy.
- Article from:
- Biotech Week
- Article date:
- December 10, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy is being applied clinically.
According to recent research from the United States, "Central nervous system malignant neoplasias, in particular, glioblastoma multiforme (GBM) have defied all current therapeutic modalities. New therapies involving tumor-targeting approach are being explored. This approach relies on the identification of unique or over-expressed cell surface receptors or antigens on tumor cells."
"In that regard, we have identified receptor for an immune regulatory cytokine, interleukin-13 (IL-13), which is over-expressed on ...